Premium
Metachromatic leukodystrophy: consequences of sulphatide accumulation
Author(s) -
Gieselmann V,
Franken S,
Klein D,
Mansson JE,
Sandhoff R,
Rauch R Lüllmann,
Hartmann D,
Saravanan VPM,
Deyn PP,
D'Hooge R,
Linden AM,
SchaerenWiemers N
Publication year - 2003
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2003.tb00225.x
Subject(s) - metachromatic leukodystrophy , medicine , leukodystrophy , metachromasia , pathology , disease , staining
Metachromatic leukodystrophy is a lysosomal lipid storage disorder. It is caused by mutations in the gene for arylsulphatase A, an enzyme involved in the degradation of the sphingolipid 3′‐O‐sulphogalactosylceramide (sulphatide). This membrane lipid can be found in various cell types, but in particularly high concentrations in the myelin of the nervous system. Patients suffer from progressive, finally lethal, demyelination due to accumulation of sulphatide. In the nervous system, lipid storage not only affects oligodendrocytes but also neurons and, in addition, leads to astrogliosis and activation of microglia. At the cellular level, lysosomal sulphatide storage also affects the lipid composition of myelin itself and has consequences for the amount and localization of particular myelin membrane‐associated proteins. Here we review data, largely based on an arylsulphatase A knock‐out mouse model of metachromatic leukodystrophy. Conclusion : The knock‐out mouse model of metachromatic leukodystrophy has provided insights into the histopathological and cellular consequences of sulphatide storage.